drugset / Trial / NCT04412408
Study on Sintilimab in Stage IV High Risk Neuroblastoma
NaSingle-groupOpen-labelTreatment
Summary
A phase I observational study on the safety and efficacy of treatment of recurrent stage IV high risk neuroblastoma with Nivolumab
Timeline
- Start
- 2020-09-01
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 2 mg/kg | Intravenous |